Vanderbilt-Ingram Cancer Center

The VICC.ORG Investigator Directory

Craig W. Lindsley, Ph.D.

Associate Professor of Pharmacology and Chemistry
Director, Medicinal Chemistry
Director, The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
VICC Member
Researcher

Contact Information:

Vanderbilt University Medical Center
Department of Pharmacology
1205 Light Hall
Nashville, TN 37232-0697
615-322-8700
Fax: 625-343-6532

Research Specialty:

Medicinal chemistry efforts to validate novel targets/mechanisms

Research Description:

The major focus of the Lindsley laboratory is drug discovery and medicinal chemistry. Students in my lab will collaborate with other members of the Pharmacology, Drug Metabolism and Clinical Pharmacology departments to pursue small molecule hits from high throughput screens, perform lead optimization studies to develop structure-activity-relationships (SAR) and ultimately deliver small molecules with acceptable properties to validate novel targets/mechanisms in in vivo animal models of target diseases. The molecular targets of interest are kinases, GPCRs, ion channels, nuclear hormone receptors and protein-protein interactions, with an emphasis on allosteric modulation as opposed to classical agonism/antagonism. Therapeutic areas of interest span cancer, neuroscience (schizophrenia, anxiety, pain, sleep, Parkinson's disease) and endocrinology (diabetes, obesity). Students will be exposed to every phase of classical drug discovery. As a member of ther Vanderbilt Institutue of Chemical Biology, training in my laboratory will be broad and involve organic synthesis, medicinal chemistry, pharmacology and drug metabolism. For many programs in the neuroscience area, students will have the opportunity to also develop radioligands for binding assay development and PET tracers for imaging studies.

Another focus in the group is parallel synthesis and the development of new technologies for library synthesis. The lab has state-of-the-art microwave synthesis technology, a mass-directed HPLC purification platform and a large collection of monomers and polymer-supported reagents. There are a number of projects directed at synthesizing libraries of small molecule protein-protein inhibitors, target family-directed libraries and other drug-like small molecule libraries for use in high throughput screening efforts.

The third area of interest in my group is synthetic organic chemistry. Students will have the opportunity to work on synthetic methodology projects as well as partial and total synthesis projects.

Publications:

• Sheffler, DJ, Williams, R, Bridges, TM, Xiang, Z, Kane, AS, Byun, NE, Jadhav, S, Mock, MM, Zheng, F, Lewis, LM, Jones, CK, Niswender, CM, Weaver, CD, Lindsley, CW, Conn, PJ A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 (M1 mAChR) Antagonist Reduces Seizures Without Impairing Hippocampal-Dependent Learning. Mol Pharmacol, 2009.
• Kennedy, JP, Conn, PJ, Lindsley, CW A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. Bioorg Med Chem Lett, 19(12), 3204-8, 2009.
• Conn, PJ, Lindsley, CW, Jones, CK Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci, 30(1), 25-31, 2009.
• Conn, PJ, Christopoulos, A, Lindsley, CW Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov, 8(1), 41-54, 2009.
• Lewis, JA, Scott, SA, Lavieri, R, Buck, JR, Selvy, PE, Stoops, SL, Armstrong, MD, Brown, HA, Lindsley, CW Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett, 19(7), 1916-20, 2009.
• Lavieri, R, Scott, SA, Lewis, JA, Selvy, PE, Armstrong, MD, Alex Brown, H, Lindsley, CW Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg Med Chem Lett, 19(8), 2240-3, 2009.
• Scott, SA, Selvy, PE, Buck, JR, Cho, HP, Criswell, TL, Thomas, AL, Armstrong, MD, Arteaga, CL, Lindsley, CW, Brown, HA Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol, 5(2), 108-17, 2009.
• Rodriguez, AL, Williams, R, Zhou, Y, Lindsley, SR, Le, U, Grier, MD, Weaver, CD, Conn, PJ, Lindsley, CW Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett, 19(12), 3209-13, 2009.
• Marlo, JE, Niswender, CM, Days, EL, Bridges, TM, Xiang, Y, Rodriguez, AL, Shirey, JK, Brady, AE, Nalywajko, T, Luo, Q, Austin, CA, Williams, MB, Kim, K, Williams, R, Orton, D, Brown, HA, Lindsley, CW, Weaver, CD, Conn, PJ Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol, 75(3), 577-88, 2009.
• Bridges, TM, Marlo, JE, Niswender, CM, Jones, CK, Jadhav, SB, Gentry, PR, Plumley, HC, Weaver, CD, Conn, PJ, Lindsley, CW Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins. J Med Chem, 2009.
• Miller, TW, Pérez-Torres, M, Narasanna, A, Guix, M, StÃ¥l, O, Pérez-Tenorio, G, Gonzalez-Angulo, AM, Hennessy, BT, Mills, GB, Kennedy, JP, Lindsley, CW, Arteaga, CL Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res, 69(10), 4192-201, 2009.
• Lindsley, CW Molecule of the month. FDA approves new treatment for fibromyalgia. Curr Top Med Chem, 9(2), 225, 2009.
• Williams, R, Niswender, CM, Luo, Q, Le, U, Conn, PJ, Lindsley, CW Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett, 19(3), 962-6, 2009.
• Fadeyi, OO, Lindsley, CW Rapid, general access to chiral beta-fluoroamines and beta,beta-difluoroamines via organocatalysis. Org Lett, 11(4), 943-6, 2009.
• Delpire, E, Days, E, Lewis, LM, Mi, D, Kim, K, Lindsley, CW, Weaver, CD Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc Natl Acad Sci U S A, 106(13), 5383-8, 2009.
• Conn, PJ, Jones, CK, Lindsley, CW Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci, 30(3), 148-55, 2009.
• Engers, DW, Niswender, CM, Weaver, CD, Jadhav, S, Menon, UN, Zamorano, R, Conn, PJ, Lindsley, CW, Hopkins, CR Synthesis and Evaluation of a Series of Heterobiarylamides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs). J Med Chem, 2009.
• Engers, DW, Rodriguez, AL, Williams, R, Hammond, AS, Venable, D, Oluwatola, O, Sulikowski, GA, Conn, PJ, Lindsley, CW Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem, 4(4), 505-11, 2009.
• Ayala, JE, Chen, Y, Banko, JL, Sheffler, DJ, Williams, R, Telk, AN, Watson, NL, Xiang, Z, Zhang, Y, Jones, PJ, Lindsley, CW, Olive, MF, Conn, PJ mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. Neuropsychopharmacology, 2009.
• Daniels, RN, Fadeyi, OO, Lindsley, CW A new catalytic Cu(II)/sparteine oxidant system for beta,beta-phenolic couplings of styrenyl phenols: synthesis of carpanone and unnatural analogs. Org Lett, 10(18), 4097-100, 2008.
• Kim, K, Miller, NR, Sulikowski, GA, Lindsley, CW A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride. Bioorg Med Chem Lett, 18(16), 4467-9, 2008.
• Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z, Wallace MA, Raab C, Lindsley CW, Sur C, Williams DL Jr "A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies." Nucl Med Biol, 35(3), 315-25, 2008.
• Lewis, JA, Lebois, EP, Lindsley, CW Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr Opin Chem Biol, 12(3), 269-80, 2008.
• Kennedy, JP, Williams, L, Bridges, TM, Daniels, RN, Weaver, D, Lindsley, CW Application of combinatorial chemistry science on modern drug discovery. J Comb Chem, 10(3), 345-54, 2008.
• Brady, AE, Jones, CK, Bridges, TM, Kennedy, JP, Thompson, AD, Heiman, JU, Breininger, ML, Gentry, PR, Yin, H, Jadhav, SB, Shirey, JK, Conn, PJ, Lindsley, CW Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther, 327(3), 941-53, 2008.
• Bridges, TM, Williams, R, Lindsley, CW Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther, 10(6), 591-601, 2008.
• Shipe WD, Barrow JC, Yang ZQ, Lindsley CW, Yang FV, Schlegel KA, Shu Y, Rittle KE, Bock MG, Hartman GD, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Uebele VN, Nuss CE, Connolly TM, Doran SM, Fox SV, Kraus RL, Marino MJ, Graufelds VK, Vargas HM, Bunting PB, Hasbun-Manning M, Evans RM, Koblan KS, Renger JJ "Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist." J Med Chem, 51(13), 3692-5, 2008.
• Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW "Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity." Bioorg Med Chem Lett, 18(1), 49-53, 2008.
• Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger J "Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels." J Med Chem, 51(20), 6471-7, 2008.
• Niswender, CM, Johnson, KA, Weaver, CD, Jones, CK, Xiang, Z, Luo, Q, Rodriguez, AL, Marlo, JE, de Paulis, T, Thompson, AD, Days, EL, Nalywajko, T, Austin, CA, Williams, MB, Ayala, JE, Williams, R, Lindsley, CW, Conn, PJ Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol, 741345, 2008.
• Bridges, TM, Lindsley, CW G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. ACS Chem Biol, 2008.
• Lindsley, CW Is Zetia a ''do nothing'' drug. Curr Top Med Chem, 8(5), 434, 2008.
• Leslie N. Aldrich, Evan P. Lebois, L. Michelle Lewis, Natalia T. Nalywajko, Colleen M. Niswender, C. David Weaver, P. Jeffrey Conn, Craig W. Lindsley "MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines." Tetrahedron Letters , 50(2), 212-215, 2008.
• R. Nathan Daniels, Kwangho Kim, Evan P. Lebois, Hubert Muchalski, Mary Hughes, Craig W. Lindsley "Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines." Tetrahedron Letters, 49(2), 305-310, 2008.
• Lindsley, CW Molecule of the month. Curr Top Med Chem, 8(12), 1100, 2008.
• Thomas, AL, Lindsley, CW Molecule of the month. Overcoming resistance. Curr Top Med Chem, 8(1), 62, 2008.
• Lindsley, CW Molecule of the month. The ''skinny'' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval. Curr Top Med Chem, 8(17), 1553, 2008.
• Zhao Z, Wolkenberg SE, Lu M, Munshi V, Moyer G, Feng M, Carella AV, Ecto LT, Gabryelski LJ, Lai MT, Prasad SG, Yan Y, McGaughey GB, Miller MD, Lindsley CW, Hartman GD, Vacca JP, Williams TM "Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)." Bioorg Med Chem Lett, 18(2), 554-9, 2008.
• Jones, CK, Brady, AE, Davis, AA, Xiang, Z, Bubser, M, Tantawy, MN, Kane, AS, Bridges, TM, Kennedy, JP, Bradley, SR, Peterson, TE, Ansari, MS, Baldwin, RM, Kessler, RM, Deutch, AY, Lah, JJ, Levey, AI, Lindsley, CW, Conn, PJ Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci, 28(41), 10422-33, 2008.
• Niswender, CM, Lebois, EP, Luo, Q, Kim, K, Muchalski, H, Yin, H, Conn, PJ, Lindsley, CW Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett, 18(20), 5626-30, 2008.
• J. Phillip Kennedy, John T. Brogan, Craig W. Lindsley "Progress toward the synthesis of piperazimycin A: exploration of the synthesis of γ-hydroxy and γ-chloropiperazic acids." Tetrahedron Letters, 49(26), 4116-4118, 2008.
• Sharma, S, Rodriguez, AL, Conn, PJ, Lindsley, CW Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett, 18(14), 4098-101, 2008.
• Miller, NR, Daniels, RN, Bridges, TM, Brady, AE, Conn, PJ, Lindsley, CW Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen. Bioorg Med Chem Lett, 18(20), 5443-7, 2008.
• Bridges, TM, Brady, AE, Kennedy, JP, Daniels, RN, Miller, NR, Kim, K, Breininger, ML, Gentry, PR, Brogan, JT, Jones, CK, Conn, PJ, Lindsley, CW Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg Med Chem Lett, 18(20), 5439-42, 2008.
• Lewis, LM, Sheffler, D, Williams, R, Bridges, TM, Kennedy, JP, Brogan, JT, Mulder, MJ, Williams, L, Nalywajko, NT, Niswender, CM, Weaver, CD, Conn, PJ, Lindsley, CW Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett, 18(3), 885-90, 2008.
• Lindsley, CW, Barnett, SF, Layton, ME, Bilodeau, MT The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets, 8(1), 7-18, 2008.
• Kennedy, JP, Brogan, JT, Lindsley, CW Total synthesis and biological evaluation of the marine bromopyrrole alkaloid dispyrin: elucidation of discrete molecular targets with therapeutic potential. J Nat Prod, 71(10), 1783-6, 2008.
• Lewis, JA, Daniels, RN, Lindsley, CW Total synthesis of Ciliatamides A-C: stereochemical revision and the natural product-guided synthesis of unnatural analogs. Org Lett, 10(20), 4545-8, 2008.
• Lindsley, CW Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns. Curr Top Med Chem, 8(13), 1158, 2008.
• Daniels, R Nathan, Lindsley, Craig W A new, non-SSRI mechanism of action for Prozac. Curr Top Med Chem, 7(10), 1039, 2007.
• Zhao, Z. ; Wisnoski, D.D. ; O’Brien, J.A. ; Lemiare, W. ; Williams, Jr., D.L. ; Jacobson, M.A. ; Wittman, M. ; Ha, S. ; Schaffhauser, H. ; Sur, C. ; Pettibone, D.J. ; Duggan, M.E. ; Conn, P.J. ; Hartman, G.D. ; Lindsley, C.W. "Challlenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA." Bioorg. Med. Chem. Lett., 171386-1390, 2007.
• Lindsley, Craig W Emerging from the shadow of Vioxx. Curr Top Med Chem, 7(7), 739, 2007.
• Pawluczyk, J.M. ; McClain, R.T. ; Denicola, C. ; Mulhearn, J.J. ; Rudd, D.J. ; Lindsley, C.W. "Microwave-initiated living free radical polymerization: Optimization of the preparative scale synthesis of Rasta resins’." Tetrahedron Lett., 481497-1501, 2007.
• Lindsley, C.W. ; Weaver, D. ; Conn, P.J. ; Marnett, L. "Preclinical Drug Discovery Research and Training at Vanderbilt." ACS Chem. Bio., 2(1), 17-22, 2007.
• Lindsley, CW, Weaver, D, Jones, C, Marnett, L, Conn, PJ Preclinical drug discovery research and training at Vanderbilt. ACS Chem Biol, 2(1), 17-20, 2007.
• Lindsley, Craig W, Barnett, Stanley F, Yaroschak, Melissa, Bilodeau, Mark T, Layton, Mark E Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. Curr Top Med Chem, 7(14), 1349-63, 2007.
• Shipe, W.D. ; Yang, F. ; Zhao, Z. ; Wolkenberg, S.E. ; Nolt, M.B. ; Lindsley, C.W. "Convenient and general microwave-assisted protocols for the expedient synthesis of heterocycles." Heterocycles, 70665-689, 2006.
• Nolt, M.B. ; Smiley, M.A. ; Varga, S.L. ; McClain, R.T. ; Wolkenberg, S.E. ; Lindsley, C.W. "Convenient preparation of substituted 5-amino oxazoles via a microwave-assisted Cornforth rearrangement." Tetrahedron, 62(Tetrahedron Symposia-in-Print MAOS invited), 4698-4704, 2006.
• Lindsley, C.W. ; Zhao, Z. ; Leister, W.H. ; OBrien, J.A. ; Lemiare, W. ; Williams, Jr., D.L. ; Chen, T-B. ; Chang, R.S.L. ;Burno, M. ; Jacobson, M.A. ; Sur, C. ; Kinney, G.G. ; Pettibone, D.J. ; Tiller,P.R. ; Smith, S. ;Tsou, N.N. ; Duggan, M.E. ; Conn, P.J. ; Hartman, G.D. "Design, synthesis and in vivo efficacy of novel glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-Phenyl-1-(propylsulfonyl)piperidin-4-yl] methyl benzamides." ChemMedChem, 1807-811, 2006.
• Wolkenberg, S.E. ; Zhao, Z. ; Kapitskaya, M. ; Webber, A.L. ; Pertukhin, K. ; Tang, Y.S. ; Dean, D.C. ; Hartman, George D. ; Lindsley, C.W. "Identification of potent agonists of Photoreceptor-Specific Nuclear Receptor (NR2E3) and preparation of a radioligand." Bioorg. Med. Chem. Lett., 165001-5004, 2006.
• Kausik,K.N. ; Nolt, M.B. ; Cato, M.J. ; Kane, S.A. ; Kiss, L. ; Spencer, R.H. ; Jixin Wang, J. ; Lynch, J.L. ; Regan, C.P. ; Stump, G.L. ; Li, B. ;White, R. ; Yeh, S. ; Bogusky, M.J. ; Bilodeau, M.T. ; Dinsmore, C.J. ; Lindsley, C.W. ; Hartman, G.D. ; Scott Wolkenberg S.E. ;Trotter, B.W. "Potent antagonists of the atrial IKur/Kv1.5 potassium channel: synthesis and evaluation of analogous N,N- diisopropyl-2-(pyridine-3-yl)acetamides." Bioorg. Med. Chem.Lett. , 165897-5861, 2006.
• Lindsley, C.W. ;Wolkenberg, S.E. ; Kinney, G.G. "Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors." Curr. Topics in Med. Chem., 81883-1896, 2006.
• Lindsley, C.W. ; Shipe, W.D. ; Wolkenberg, S.E. ; Theberge, C.R. ; Williams, D.L. Jr. ; Sur, C. ; Kinney, G.G. "Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia." Curr. Top. in Med. Chem., 6771-785, 2006.
• Kinney, G.G. ; O’Brien, Lemaire, W. ; Burno, M.’ Bickel, D.J. ; Clements, M.K. ; Wisnoski, D.D. ; Lindsley, C.W. ; Tiller, P.R. ; Smith, S. ; Jacobson, M.A. ; Sur, C. ; Duggan, M.E. ; Pettibone, D.J. ; Williams, Jr., D.W. "A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models." J. Pharmacol. Exp. , 313199-211, 2005.
• Lindsley, C.W. ; Zhao, Z. ; Leister, W.H. ; Robinson, R.G. ; Barnett, S.F. ; Defeo-Jones, D. ; Jones, R.E. ; Hartman, G.D. ; Huff, J.R. ; Huber, H.E. ; Duggan, M.E. "Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors." Bioorg. Med. Chem. Lett., 15761-764, 2005.
• Lindsley, C.W. ; Bogusky, M.J. ; Leister, W.H. ; McClain, R.T. ; Robinson, R. ; Barnett, S.F. ; Defeo-Jones, D. ; III Ross, C.W. ; Hartman, G.D. "Synthesis and biological evaluation of unnatural canthine alkaloids." Tetrahedron Lett., 462779-2782, 2005.
• Kim, D. ; Cheng, G.Z. ; Lindsley, C.W. ; Yang, H. ; Cheng, J.Q. "The Akt/PKB pathway: molecular target for cancer therapy." Oncogene, 247482-7492, 2005.
• Defeo-Jones, D. ; Barnett, S.F. ; Fu, S. ; Hancock, P.J. ; Haskell, K.M. ; Leander, K.R. ; McAvoy, E. ; Robinson, R.G. ; Duggan, M.E. ; Lindsley, C.W. ; Zhao, Z. ; Huber, H.E. ; Jones, R.E. "Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members." , 4271-278, 2005.
• Lindsley, C.W. ; Wisnoski, D.D. ; Leister, W.H. ;; O'Brien, J.A. ; Lemiare, W. ; Williams, Jr., D.L. ; Burno, M. ; Sur, C. ; Kinney, G.G. ; Pettibone, D.J. ; iller, P.R. ; Smith, S. ; Duggan, M.E . ; Hartman, G.D. ; Conn, P.J. ; Huff, J.R. "Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo." J. Med.Chem., 475825-5828, 2004.